

UCSF

UC San Francisco Previously Published Works

Title

Comparative Natural History of Visual Function From Patients With Biallelic Variants in BBS1 and BBS10

Permalink

<https://escholarship.org/uc/item/4f15j5sp>

Journal

Investigative Ophthalmology & Visual Science, 62(15)

ISSN

0146-0404

Authors

Pechhacker, Monika K Grudzinska
Jacobson, Samuel G
Drack, Arlene V
[et al.](#)

Publication Date

2021-12-23

DOI

10.1167/iovs.62.15.26

Peer reviewed

Comparative Natural History of Visual Function From Patients With Biallelic Variants in *BBS1* and *BBS10*

Monika K. Grudzinska Pechhacker,^{1,2} Samuel G. Jacobson,³ Arlene V. Drack,⁴ Matteo Di Scipio,⁵ Ine Strubbe,⁶ Wanda Pfeifer,⁴ Jacque L. Duncan,⁷ Helene Dollfus,^{8,9} Nathalie Goetz,⁹ Jean Muller,⁸⁻¹⁰ Andrea L. Vincent,^{11,12} Tomas S. Aleman,¹³⁻¹⁵ Anupreet Tumber,¹ Caroline Van Cauwenbergh,^{6,16} Elfride De Baere,¹⁶ Emma Bedoukian,¹⁵ Bart P. Leroy,^{6,13,15-17} Jason T. Maynes,^{18,19} Francis L. Munier,²⁰ Erika Tavares,^{1,5} Eman Saleh,⁵ Ajoy Vincent,^{1,2,5} and Elise Heon^{1,2,5}

¹Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, Canada

²Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada

³Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States

⁴Department of Ophthalmology, Institute for Vision Research, University of Iowa, Iowa City, Iowa, United States

⁵Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada

⁶Department of Ophthalmology, Ghent University Hospital & Department of Head and Skin, Ghent University, Ghent, Belgium

⁷Department of Ophthalmology, University of California, San Francisco, San Francisco, California, United States

⁸CARGO (*Centre de référence pour les affections rares génétiques*), IGMA *Institut de Génétique Médicale d'Alsace*, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

⁹UMRS_1112, IGMA (*Institut de génétique Médicale d'Alsace*) Université de Strasbourg, Strasbourg, France

¹⁰Laboratoire de diagnostic génétique, IGMA (*Institut de génétique Médicale d'Alsace*) Hôpitaux Universitaires de Strasbourg, Strasbourg, France

¹¹Department of Ophthalmology, New Zealand National Eye Centre, University of Auckland, Auckland, New Zealand

¹²Eye Department, Greenlane Clinical Centre, Auckland District Health Board, Auckland, New Zealand

¹³Center for Advanced Retinal and Ocular Therapeutics, Perelman School of Medicine, Philadelphia, Pennsylvania, United States

¹⁴Scheie Eye Institute at the Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States

¹⁵Division of Ophthalmology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

¹⁶Center for Medical Genetics, Ghent University and Ghent University Hospital, Ghent, Belgium

¹⁷Center for Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

¹⁸Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada

¹⁹Departments of Biochemistry and Anesthesiology and Pain Medicine, University of Toronto, Program in Molecular Medicine, The Hospital for Sick Children, Toronto, Canada

²⁰Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland

Correspondence: Elise Heon, Professor of Ophthalmology, Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1 x 8, Canada; elise.heon@sickkids.ca.

Received: December 7, 2020

Accepted: November 19, 2021

Published: December 23, 2021

Citation: Grudzinska Pechhacker MK, Jacobson SG, Drack AV, et al. Comparative natural history of visual function from patients with biallelic variants in *BBS1* and *BBS10*. *Invest Ophthalmol Vis Sci*. 2021;62(15):26. <https://doi.org/10.1167/iovs.62.15.26>

PURPOSE. The purpose of this study was to compare the natural history of visual function change in cohorts of patients affected with retinal degeneration due to biallelic variants in Bardet-Biedl syndrome genes: *BBS1* and *BBS10*.

METHODS. Patients were recruited from nine academic centers from six countries (Belgium, Canada, France, New Zealand, Switzerland, and the United States). Inclusion criteria were: (1) female or male patients with a clinical diagnosis of retinal dystrophy, (2) biallelic disease-causing variants in *BBS1* or *BBS10*, and (3) measures of visual function for at least one visit. Retrospective data collected included genotypes, age, onset of symptoms, and best corrected visual acuity (VA). When possible, data on refractive error, fundus images and autofluorescence (FAF), optical coherence tomography (OCT), Goldmann kinetic perimetry (VF), electroretinography (ERG), and the systemic phenotype were collected.

RESULTS. Sixty-seven individuals had variants in *BBS1* ($n = 38$; 20 female patients and 18 male patients); or *BBS10* ($n = 29$; 14 female patients and 15 male patients). Missense variants were the most common type of variants for patients with *BBS1*, whereas frameshift variants were most common for *BBS10*. When ERGs were recordable, rod-cone dystrophy (RCD) was observed in 82% (23/28) of patients with *BBS1* and 73% (8/11) of patients with *BBS10*; cone-rod dystrophy (CORD) was seen in 18% of patients with *BBS1* only, and cone dystrophy (COD) was only seen in 3 patients with *BBS10* (27%). ERGs were

nondetectable earlier in patients with *BBS10* than in patients with *BBS1*. Similarly, VA and VF declined more rapidly in patients with *BBS10* compared to patients with *BBS1*.

CONCLUSIONS. Retinal degeneration appears earlier and is more severe in *BBS10* cases as compared to those with *BBS1* variants. The course of change of visual function appears to relate to genetic subtypes of BBS.

Keywords: blindness, Bardet Biedl syndrome, retinal degeneration, genetics, natural history, end points

Bardet-Biedl syndrome (BBS) has a broad range of clinical features that typically include severe photoreceptor degeneration often combined with truncal obesity, postaxial polydactyly, autism-like behavior, cognitive impairment, hypogonadism, and renal anomalies, among other features.^{1–6} Biallelic variants have been identified in 24 *BBS* genes,^{7,8} where *BBS1* and *BBS10* together are the most commonly involved.^{9,10} BBS is considered a ciliopathy as the underlying genes are expressed in primary cilia.^{11,12} *BBS1*, together with seven other BBS proteins form a protein complex named BBSome, a key regulator of the ciliary membrane proteome, important for ciliary transport.^{13,14} Whereas, *BBS10* protein form a complex with two other chaperonin-like proteins responsible for BBSome assembly.¹⁵

Bardet-Biedl syndrome is phenotypically and genetically heterogeneous, and demonstrates considerable phenotypic and mechanistic overlap with other ciliopathies, such as Joubert syndrome and Senior-Løken syndrome.^{1,2,4,5,16–25} The systemic features of BBS vary among affected individuals but photoreceptor dysfunction is a constant finding. In some patients, retinal degeneration may be the only manifestation of BBS-related variants (e.g. *BBS1* and *C8orf37*),^{26,27} which was also observed for other ciliopathy genes (e.g. *CEP290*) causing syndromic and non-syndromic retinal degeneration.²⁸ Hence, genetic testing is required to identify the pathogenic variants in *BBS* gene to confirm *BBS*-related disease.

The retinal degeneration associated with BBS is usually early and severe. The phenotypes observed include rod-cone dystrophy (RCD), cone-rod dystrophy (CORD), or cone dystrophy (COD).^{29–34} Central and peripheral visual function loss are most noticeable by the second or third decade of life when 73% of affected individuals become legally blind.^{1,30} Studies of murine models suggest that the photoreceptor degeneration could be due to the accumulation of non-outer segment proteins in the outer segment, rather than failure of protein delivery to the outer segment.³⁵

It is important to identify *BBS*-related disease especially that a recent mice model study suggests that *BBS10*-related disease could be treatable, (Drack AV, et al. IOVS 2021; 62: ARVO E-Abstract 1178). Lessons learned from early gene therapy studies for Leber congenital amaurosis (LCA) due to biallelic pathogenic variants in *RPE65* gene highlight the importance of natural history information in patient selection and choosing the useful outcome measures to best interpret results of clinical treatment trials.^{36,37}

This international collaborative effort allowed collection of data from patients with retinal degeneration and biallelic variants in the two most commonly involved BBS genes; *BBS1* and *BBS10* (hereon referred to as patients with *BBS1* and patients with *BBS10*). We compared the ocular phenotype of patients with *BBS1* and patients with *BBS10* to gain

insight into the natural history of visual function loss over time.

METHODS

This retrospective study involved nine participating centers across six countries (Belgium, Canada, France, New Zealand, Switzerland, and the United States,) and was approved by the institutional ethics review board of each participating center and the procedures followed the tenets of the Declaration of Helsinki. Patients were identified through the respective internal databases. Inclusion criteria were: (1) female or male subjects with retinal degeneration, (2) biallelic pathogenic or presumed pathogenic variants in *BBS1* or *BBS10* genes, and (3) availability of ocular and systemic phenotype information for at least one visit. The patient's evaluation and genetic counseling were provided according to the best standard of care practice of each institution. For those countries in the European Union, the Oviedo Convention and the Treaty of Lisbon were honored. Data collected and analyzed included de-identified demographic information, ocular and medical history, systemic phenotype, DNA genetic results and parameters of the ocular phenotype (visual acuity [VA], Goldmann kinetic perimetry [VF], and electroretinography [ERG]). In selected cases, optical coherence tomography (OCT) scans were also reviewed. Full data sets were not available for all subjects for all testing parameters and some patients only had data from one visit (Table 1).

Visual Function Assessment

Data available from full field ERGs were collected from patient' charts at different ages when possible. ERGs were performed incorporating standards of The International Society for Clinical Electrophysiology of Vision (ISCEV) using Diagnosys LLC system (Canada, France, and the United States) or RETI-port system, Roland Consult (Belgium and New Zealand).^{38,39} ERG results were interpreted by each principal investigator and categorized as RCD, CORD, COD, or non-detectable (ND) at first visit. The RCD pattern referred to the reduced rod and cone photoreceptor responses with predominantly reduced rod ERGs; the CORD pattern referred to reduction in cone and rod ERG responses but predominantly reduced cone responses; and the COD phenotype referred to a reduction in cone responses with preserved rod responses. ND referred to severely reduced responses not discernable from noise.

TABLE 1. Demographic Information and Summary of Ocular Assessments

Parameter/Study Group	BBS1 (<i>n</i> = 38)	BBS10-RCD* (<i>n</i> = 26)	BBS10-COD (<i>n</i> = 3)
Sex, <i>n</i> (%)			
Female	20 (51)	13 (50)	1 (33)
Male	18 (49)	13 (50)	2 (67)
Ethnicity, <i>n</i> (%)			
Caucasian	28 (76)	18 (62)	3 (100)
Asian	2 (5)	0 (0)	0 (0)
Hispanic	1 (3)		
Unknown	6 (16)	10 (38)	0 (0)
Age at initial visit, years			
Mean	18.2	12.9	19.5
Range	(3.0-49.0)	(2.0-45.0)	(10.2-33.4)
Age at last visit, years			
Mean	27.3	21.3	32
Range	(5.0-58.0)	(2.0-53.0)	(25.0-41.1)
Observation time			
Mean, years	10.1	8.3	12
Range, years	(0-33.9)	(0-19.0)	(7.7-15.2)
No. of visits			
Mean, <i>n</i>	5	6	5
Range, <i>n</i>	(1.0-15.0)	(1.0-13.0)	(3-8)
Refraction, <i>n</i> (%)			
Myopia	13 (50)	13 (56)	3 (100%)
Hyperopia	11 (42)	8 (30)	0 (0)
Emmetropia	2 (8)	3 (13)	0 (0)
Astigmatism >2 D	12 (46)	13 (48)	1 (33)
Cataract, <i>n</i> (%)			
Age of onset	27.2	18.4	33.4
Mean, years	8.5-47.8	13.6-25.0	NA
Range, years		13 (81)	NA
Nyctalopia, <i>n</i> (%)			
Age of onset	24 (86)	13 (81)	0 (0) at age 33.4
Mean, years	19.4	10	NA
Range, years	5.0-35.9	2.0-19.3	NA
Photophobia, <i>n</i> (%)			
Age of onset	18 (72)	13 (81)	1 (33)
Mean, years	22.5	15.2	36.0
Range, years	8.0-47.8	12.1-26.5	NA

COD, cone dystrophy; RCD, rod-cone dystrophy; *n*, number *includes individuals with non-detectable ERG at first visit but symptomatology of RCD; NA, not applicable.

Data availability: BBS1 (*n* = 26 for refraction, *n* = 35 for cataract, *n* = 28 for nyctalopia, and *n* = 25 for photophobia); BBS10-COD (*n* = 2 for cataract); severe BBS10 (*n* = 23 for refraction, *n* = 19 for cataract, *n* = 16 for nyctalopia, and *n* = 17 for photophobia).

Visual Acuity

The methods of VA assessment included preferential looking Teller acuity cards for preverbal children and Snellen acuity charts, or decimal (France), for older individuals. VA data for children ≤ 5 years of age were excluded due to poor reliability. All VA measurements were converted to logarithm of the minimum angle of resolution (LogMAR). Because refractive errors were not documented for all patients in some cases it was uncertain if the best correction was used. For this reason, we refer to VA and not BCVA. For the purpose of data analyses, patients who could only count fingers (CFs), perceive hand motion (HM), had only light perception (LP) or no light perception (NLP) were assigned LogMAR values of 2.6, 2.7, 2.8, and 2.9, respectively.^{40,41} Acuity of each eye was measured separately but, for analyses, VA results are presented as an average of both eyes.

For patients with ≥ 5 data points, simple linear regression analyses of VA by age were performed for data from both BBS1 and BBS10 cohorts.

Refraction

Refractions were available for 62% of patients with BBS1 and 93% of patients with BBS10. Myopia was defined as a spherical equivalent < -0.5 diopters (D), hyperopia as a spherical equivalent $\geq +1.0$ D and significant astigmatism as ≥ 2 D of cylinder. Results are presented as a mean spherical equivalent from both eyes.

Visual Fields

Goldmann kinetic perimetry assessments were collected at different ages for each eye. The outcome measure was the diameter across horizontal meridians for each stimulus tested (III4e and V4e). Due to symmetry, the end point was the average value from both eyes. Longitudinal and cross-section analyses of the VF to the III4e and V4e stimuli were available for some individuals and simple linear regression analyses were performed on both cohorts as described for

TABLE 2. Summary of Systemic Features and Variants in all Cases

Pt. no.	Dev										Reference							
	Digit Anomaly	Kidney Anomalies	Liver Anomalies	Hearing Anomalies	Cardiac Abnormalities	Diabetes	Ataxia/Poor Coordination	Cognitive Impairment	Delay/Learning Disabilities	Speech Disorder/Delay		Behavioral Abnormalities	Genital Abnormalities					
1	+	NA	NA	-	-	-	-	NA	NA	-	-	-	Arg160Gln	Variant 1	Arg160Gln	Variant 2	Arg160Gln	1
2	NA	+	+	-	-	-	-	-	+	+	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Asn524del	1,2
3	+	+	+	+	-	+	-	NA	+	-	+	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	1
4	+	+	+	+	-	+	-	NA	+	+	+	NA	Ile330Thr	Met1?	Met1?	Met1?	Met1?	1-3
5	+	+	+	+	-	+	-	-	+	+	+	+	Met1?	Met1?	Met1?	Met1?	Met1?	1
6	+	+	+	+	-	+	-	-	+	+	+	+	Met1?	Met1?	Met1?	Met1?	Met1?	1
7	+	+	+	+	-	+	-	-	+	+	+	+	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	1,3,4
8	+	+	+	+	-	+	-	-	+	+	+	+	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	1
9	+	+	+	+	-	+	-	-	+	+	+	+	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	1
10	+	+	+	+	-	+	-	-	+	+	+	+	Ile296Thrfs*7	Ile296Thrfs*7	Ile296Thrfs*7	Ile296Thrfs*7	Ile296Thrfs*7	1,4
11	+	+	+	+	-	+	-	NA	+	-	-	+	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	1
12	+	+	+	+	-	+	-	NA	+	-	-	+	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	1,3
13	+	+	+	+	-	+	-	-	+	-	+	+	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	1,3
14	+	+	+	+	-	+	-	-	+	-	+	+	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	1
15	+	+	+	+	-	+	-	-	+	-	+	+	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	1
16	+	+	+	+	-	+	-	-	+	-	+	+	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	1
17	+	+	+	+	-	+	-	NA	+	-	+	+	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	1
18	+	+	+	+	-	+	-	-	+	-	+	+	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
19	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
20	+	+	+	+	-	+	-	NA	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
21	+	+	+	+	-	+	-	NA	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
22	+	+	+	+	-	+	-	NA	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
23	+	+	+	+	-	+	-	NA	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
24	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
25	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
26	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
27	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
28	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
29	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
59	+	+	+	+	-	+	-	NA	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
60	+	+	+	+	-	+	-	NA	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
61	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
62	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
63	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
64	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
65	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
66	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New
67	+	+	+	+	-	+	-	-	+	-	-	-	Met390Arg	Met390Arg	Met390Arg	Met390Arg	Met390Arg	New

TABLE 2. Continued

Pt. no.	Digit Anomaly	Kidney Anomalies	Liver Anomalies	Hearing Anomalies	Cardiac Abnormalities	Diabetes	Ataxia/Poor Coordination	Cognitive Impairment	Delay/Learning Disabilities	Speech Disorder/Delay	Behavioral Abnormalities	Genital Abnormalities	Variant 1	Variant 2	Reference
													Dev		
30	+	-	-	+	-	+	+	+	+	+	+	+	Arg49Trp	Arg49Trp	1,4
31	+	+	+	-	-	-	-	-	+	-	-	NA	Cys91Leufs ⁵	Val707*	1,2,4
32	+	+	+	-	-	-	-	+	+	+	+	+	Cys91Leufs ⁵	Glu104Lysfs*7	1,3,4
33	+	+	+	-	NA	-	NA	+	+	+	+	+	Cys91Trp	Ala474Metfs*10	1-4
34	+	+	+	-	NA	-	NA	-	+	+	-	-	Cys91Trp	Ala474Metfs*10	1-4
35	+	+	+	-	NA	+	+	+	+	+	NA	+	Cys91Leufs ⁵	Tyr559*	1,4
36	+	+	NA	-	NA	NA	NA	+	+	NA	+	+	Cys91Leufs ⁵	Tyr469*	1,3
37	+	+	-	-	-	-	-	+	+	+	-	+	Cys91Leufs ⁵	Tyr469*	1,3
38	+	+	-	-	-	-	-	-	+	+	-	+	Cys91Leufs ⁵	Tyr469*	1,3
39	+	-	-	-	-	-	-	-	-	-	-	NA	Ile407Thr	Ile407Thr	1,3
40	-	-	-	-	-	-	-	-	NA	NA	NA	-	Glu61*	Leu76Phe	
41	-	-	-	-	-	-	-	+	NA	NA	NA	-	Glu61*	Leu76Phe	
42	+	+	-	-	-	+	-	NA	NA	NA	NA	+	Cys91Leufs ⁵	Tyr177*	4
43	-	+	-	-	-	+	-	+	+	+	+	+	Ser303Argfs*3	His656Leufs*4	4
44	+	+	-	-	-	-	+	+	+	-	+	-	Cys91Leufs ⁵	Cys91Leufs ⁵	3
45 ^(a)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Asn364Thrfs*5	Thr524Alafs*13	
46 ^(p)	+	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Tyr589*	Tyr589*	
47	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Leu76Ilefs*34	Cys91Leufs ⁵	
48	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cys91Leufs ⁵	Phe861Leu	
49	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Arg49Trp	Cys91Leufs ⁵	
50	+	NA	NA	NA	NA	NA	NA	NA	+	NA	NA	NA	Ser444Valfs*44	Arg49Trp	
51	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cys91Leufs ⁵	Cys91Leufs ⁵	
52	+	-	-	+	-	-	NA	+	+	-	NA	+	Arg49Trp	Arg49Trp	
53	+	-	-	+	-	-	NA	+	+	-	NA	+	Arg49Trp	Arg49Trp	
54	+	+	-	+	+	-	NA	+	+	-	NA	-	Arg49Trp	Arg49Trp	
55	+	+	NA	+	+	-	NA	+	-	-	-	-	Leu414Ser	Cys91Leufs ⁵	4
56	+	-	-	-	-	-	+	-	-	-	-	-	Cys91Leufs ⁵	Pro350Ilefs*11	
57	+	-	-	-	-	-	-	+	-	-	+	+	Arg49Trp	Arg49Trp	
58	+	+	+	-	+	+	-	-	-	-	-	+	Cys91Leufs ⁵	Cys91Leufs ⁵	4

(a) Hirschsprung disease; (p) heterotaxia. NA: not available. -: not present, +: present.

Summary of systemic phenotypes in patients with BBS1 and patients with BBS10

Feature	BBS1, n (%)		BBS10, n (%)	
	n	%	n	%
Digit anomalies	32	34 (94)	21	24 (88)
Developmental delay/learning disabilities	23	32 (72)	14	19 (74)
Cognitive impairment	14	29 (48)	13	21 (62)
Kidney anomalies	15	33 (45)	12	22 (55)
Behavioral abnormalities	8	21 (38)	7	15 (47)
Ataxia/poor coordination	10	31 (32)	7	16 (44)
Genital anomalies	7	22 (32)	10	18 (56)
Speech disorder	10	34 (29)	7	17 (41)
Liver anomalies	8	32 (25)	4	20 (20)
Hearing problems	8	34 (24)	5	22 (23)
Diabetes	8	34 (24)	5	21 (24)
Cardiac anomalies	4	34 (12)	2	21 (10)

NA, not applicable.

TABLE 3. Reported Variants in BBS1 and BBS10 and Their Corresponding Predictive Scores

Gene	Variant	Predicted Effect	dbSNP*	PhyloP†	SIFT/PolyPhen-2‡	Allele frequency (GnomAD)§	Splicing¶	Access Number¶¶ (ClinVar or Uniprot)	
BBS1	c.1A>G, p.(Met1?)	Startloss	rs1306821707	NA	NA	0.000003989	Truncation from start	Lik. Pat. RCV0000671318.1	
	c.479G>A, p.(Arg160Gln)	Missense, splicing	rs376894444	5.13	0.07/0.947	0.0000278	NNSPLICE: 91.5%	Pat. RCV001074216.1	
	c.480-1G>C, p.?	Likely skip exon 6	rs1057516933	NA	NA	0	NNSPLICE: -100.0%	Lik. Pat. RCV000409654.1	
	c.724-8_726del, p.?	Likely skip exon 9	NA	NA	NA	0	Premature stop	Lik. Pat. RCV001073554.1	
	c.887del, p.(Ile296Thrfs*7)	Frameshift stop	rs794727006	NA	NA	0	Premature stop	Pat. VCV000193740.2	
	c.989T>C, p.(Ile330Thr)	Missense	NA	4.48	0.3/0.730	0	NA	Lik. Pat-VAR_066278	
	c.1150G>T, p.(Glu384*)	Nonsense	NA	4.56	NA	0	Premature stop	Novel	
	c.1169T>G, p.(Met390Arg)	Missense	rs113624356	3.76	0.01/0.347	0.001570	NA	Pat. RCV000787785.1	
	c.1214_1215insSVA, p.(Thr405Thrfs*46)	Frameshift stop	NA	NA	NA	NA	NA	Pat. SCV001245066.1	
	c.1340-1G>T, p.?	Likely skip exon 14	NA	NA	NA	0	NNSPLICE: -100.0%	Lik. Pat. RCV000669016.1	
	c.1447C>T, p.(Arg483*)	Nonsense	NA	4.48	NA	NA	Premature stop	Pat. RCV000804705.1	
	c.1473+2T>C, p.?	Likely skip exon 14	NA	4.0	NA	0	NNSPLICE: -100.0%	Lik.Pat. VCV000866282.1	
	c.1514_1515del, p.(Leu505Profs*52)	Frameshift stop	rs775769424	NA	NA	0.00001395	Premature stop	Pat. RCV000410181.2	
	c.1568_1570del, p.(Asn524del)	Inframe deletion	rs863224782	4.24	NA	0.000003976	NA	Unc. RCV000198771.1	
	BBS10	c.145C>T, p.(Arg49Trp)	Missense	rs768933093	1.17	0/0.998	0.00009558	NA	Pat. RCV000799037.2
	c.181G>T, p.(Glu61*)	Nonsense	NA	1.09	NA	0	0	Premature stop	Novel
	c.224_225dup, p.(Leu761lefs*34)	Inframe deletion	NA	NA	NA	0	0	Premature stop	Novel
c.226C>T, p.(Leu76Phe)	Missense	rs767638924	2.1	0.16/0.905	0.000004177	NA	NA	Novel	
c.258T>A, p.(Phe86Leu)	Missense	NA	0.12	0/0.962	0	NA	NA	Novel	
c.271dup, p.(Cys91Leufs*5)	Nonsense	rs549625604	NA	NA	0.0005642	Premature stop	Pat. RCV001074512.1		
c.273C>G, p.(Cys91Trp)	Missense	rs148374859	0.45	0/0.928	0.00002816	NA	NA	Pat. RCV000023803.5	
c.310_311del, p.(Glu104Lysfs*7)	Frameshift stop	NA	NA	NA	0	Premature stop	Novel		
c.531C>A, p.(Tyr177*)	Nonsense	rs863224522	0.29	NA	0	Premature stop	Lik. Pat. RCV000409505.1		
c.909_912del, p.(Ser303Argfs*3)	Frameshift stop	rs780059308	NA	NA	0.00001774	Premature stop	Pat. RCV000811417.1		
c.1044_1045del, p.(Pro350Ilefs*11)	Frameshift stop	rs587777837	NA	NA	0	Premature stop	Pat. RCV000023802.7		
c.1091del, p.(Asn364Thrfs*5)	Frameshift stop	rs727503818	NA	NA	0.00006738	Premature stop	Pat RCV001004383.1		
c.1220T>C, p.(Ile407Thr)	Missense	rs750164736	0.85	0.19/0.006	0.000007958	NA	NA	Novel	
c.1241T>C, p.(Leu414Ser)	Missense	rs786204575	2.06	0.3/0.339	0.000003979	NA	NA	Lik. Pat. RCV000169317.1	
c.1330del, p.(Ser444Valfs*44)	Frameshift stop	NA	NA	NA	0	Premature stop	Novel		
c.1407T>G, p.(Tyr469*)	Nonsense	rs1356713858	0.61	NA	0.000006977	Premature stop	Pat. RCV000779832.1		

TABLE 3. Continued

Gene	Variant	Predicted Effect	dbSNP*	PhyloP†	SIFT/PolyPhen-2‡	Allele frequency (GnomAD)§§	Splicing	Access Number¶¶ (ClinVar or Uniprot)
	c.1420_1432del, p.(Ala474Metfs*10)	Frameshift stop	NA	NA	NA	NA	Premature stop	Novel
	c.1566_1569dup, p.(Thr524Alafs*13)	Frameshift stop	NA	NA	NA	0	Premature stop	Novel
	c.1677C>A, p.(Tyr559*)	Nonsense	rs375413604	NA	NA	0.00004252	Premature stop	Pat. RCV000477827.2
	c.1767C>A, p.(Tyr589*)	Nonsense	NA	NA	NA	NA	Premature stop	Lik. Pat. RCV000760514.1
	c.1967del, p.(His656Leufs*4)	Frameshift stop	NA	NA	NA	0	Premature stop	Novel
	c.2119_2120del, p.(Val707*)	Nonsense	rs775950661	NA	NA	0.00006015	Premature stop	Pat. RCV000665753.1

* Database of single nucleotide polymorphisms (dbSNP); <http://www.ncbi.nlm.nih.gov/SNP/>.

† PhyloP basewise conservation score derived from alignment of 46 vertebrate species (range = -14.1 to 6.4). Higher levels are more conserved (Pollard KS, Hubisz MJ, Siepel A. *Detection of non-neutral substitution rates on mammalian phylogenies* Genome Res. 2010 Jan;20(1):110-21. PMID: 19858363).

‡ Missense predictors: SIFT(predicts whether an amino acid substitution affects protein function based on sequence homology and the physical properties of amino acids; <https://sift.bii.a-star.edu.sg/>)/Polyphen(predicts possible impact of an amino acid substitution on the structure and function of a human protein using straightforward physical and comparative considerations; <http://genetics.bwh.harvard.edu/pph2/>).

§ Allele frequency across multiple populations from Genome Aggregation Database (GnomAD); <https://gnomad.broadinstitute.org/>.

|| Splicing predictor (Splice prediction by Neural Network; https://www.fruitfly.org/seq_tools/splice.html).

¶¶ ClinVar (archive of reports of the relationships among human variations and phenotypes, with supporting evidence; <https://www.ncbi.nlm.nih.gov/clinvar/intro/>) or Uniprot (high-quality and freely accessible resource of protein sequence and functional information; <https://www.uniprot.org/>).

Pat., pathogenic; Lik. Pat., likely pathogenic; Unc, inconclusive.

VA. A point plot graph also was performed on both cohorts with III4e data, as described below.

Data Analysis

Data were collected and summarized using descriptive measures, including means with standard deviations (SDs) and medians with ranges for continuous variables such as age, and frequencies and percentages for categorical variables, such as gender. Simple linear regression analyses were analyzed in base R and graphed in ggplot2 (<https://ggplot2.tidyverse.org>) in RStudio (<http://www.rstudio.com/>).^{42,43}

Genetic Analysis

Genetic diagnosis was performed through different laboratories: Molecular Genetics Laboratory of Ghent University Hospital (Belgium); the Diagnostic Genetics Laboratory at Strasbourg University Hospital (France); John & Marcia Carver Nonprofit Genetic Testing Laboratory and Prevention Genetics (United States); and the Genetic Diagnostics in Tubingen and other CLIA-approved laboratories (for Canada, New Zealand, and the United States). Cases for which some data were previously published are referenced in Table 2. Mutations were verified to adhere to the latest nomenclature of the Human Genome Variation Society recommendations (*BBS1* [NM_024649] and *BBS10* [NM_024685.4], <https://varnomen.hgvs.org>).⁴⁴ Prediction of the pathogenicity of variants used tools publicly available. Our approach to assess the pathogenicity of variants using predictive algorithms is outlined in Table 3. The structure of BBS10 protein was modeled with Phyre2, using the cryo-EM structure of the mammalian chaperonin TRiC/CCT (PDB ID 3IYG) and the X-ray crystal structures of GroEL/GroES (PDB IDs 1SVT and 1Q3S) as templates.^{45–49}

RESULTS

Demographic Information

A total of 67 patients with biallelic disease-causing variants in the *BBS1* and *BBS10* genes were included. Thirty-eight of all patients with BBS had presumed pathogenic variants in *BBS1* (52% female patients and 48% male patients) and 29 in *BBS10* (50% female patients and 50% male patients). The majority of the cohort was of Caucasian ancestry with less than 1% of Asian origin (India/Pakistan). The information about consanguinity was not reported in the patient charts. The age of patients at their first visit ranged from 2 to 49 years with mean duration of observation time of 9.7 years and mean number of 6 visits (see Table 1).

Electrophysiological Phenotype

Overall, data from ERG assessments were available for 51 patients (76%; $n = 35$ for *BBS1*, and $n = 16$ for *BBS10*). Seven patients with *BBS1* (20% of patients with *BBS1*) had a non-recordable ERG (mean age = 22 years), whereas this was in 5 out of 16 (31%) patients with *BBS10* (mean age = 16 years).

Of the *BBS1*-recordable ERGs, 22 (78%, 7.8–27 years) showed RCD and 6 cases (21%, 15.1–35.2 years) showed a COD phenotype. Of the 11 (69%) recordable *BBS10*-ERGs, an RCD pattern was documented in 8 cases (73%, 4–16.3 years) whereas 3 patients with *BBS10* (cases 39, 40, 41) had a

stable or very slowly progressive COD phenotype (see Table 1). For these 3 patients with *BBS10*-COD, light-adapted (LA) photopic ERGs were severely reduced at the mean age of 22.3 years (12–39 years) and rod responses were normal (Fig. 1D). In Case 39, ERGs performed at ages 34 and 39 years showed no progression.

Visual Acuity

A total of 139 VA measurements (mean 5/patient, range of 1–15) were available for *BBS1* (age ranged = 5–47.8 years); and 143 VA measurements (mean 5/patient, range of 1–13) for patients with *BBS10* (5–41 years). Not all measurements were available from all subjects at all visits. In the first decade, the VA profiles of patients with *BBS1* and patients with *BBS10* were similar, after which the rate of VA decline increased earlier in the *BBS10* cohort (approximately 15 years) than in the *BBS1* cohort (approximately 25 years; Fig. 2A). The greatest vision loss was documented in the late teenage years (*BBS10*) and early adulthood (*BBS1*).

A very slow progression in VA loss was observed in three patients with *BBS10* with COD. At the mean age of 20 years, VA for patients with *BBS10*-COD and patients with RCD were 0.5 LogMAR and 1.5 LogMAR, respectively; whereas for patients with *BBS1* at the mean age of 20 years, the mean VA was 0.85 LogMAR. One patient with *BBS1* developed NLP vision (2.9 LogMAR) at the age of 16 years, before which time he recalled symptoms of nyctalopia. VA of LP (2.8 LogMAR) was reported in 2 patients with *BBS1* at the mean age of 40.3 years and 4 patients with *BBS10* at the mean age of 25 years (20–27 years).

The patients with *BBS10*-COD had different levels of reduced visual acuity (case 39; 0.95 LogMAR age 41 years, case 40; 0.5 LogMAR age 14.8 years and case 41; 0.15 LogMAR age 10.2 years) suggesting a slow decline over time though patients reported VA to be stable.

Visual Fields

Goldmann VFs were available for 20 (69%) patients with *BBS1* (9–47.8 years); and 14 (50%) patients with *BBS10* (9–38.6 years). Isopters used were either III4e, V4e, or combined. The sample size of responses to V4e was small, hence not shown.

Although there was variability between the different genes and mutations involved and within age groups, there was a clear inverse relationship between age and VF diameter for both III4e and V4e isopters in patients with *BBS1* and in patients with *BBS10*-RCD (see Fig. 2B). Despite the variability, as observed for the visual acuity changes, visual field narrowing in patients with *BBS10* was earlier and somewhat greater than in patients with *BBS1*.

In patients with *BBS10* with RCD, the III4e isopter became unrecordable by the age of 25 years, whereas at the same age, patients with *BBS1* had on average ≥ 20 degrees of preserved field to this isopter. Although GVFs in patients with *BBS10* with RCD were not detectable to either the III4e or V4e stimulus at the age of 33, 10 of 13 (77%) of patients with *BBS1* aged 30 years or older had a recordable field (range of 5–40 degrees to the III4e, IV4e, or V4e stimuli [average 20 degrees]).

At the age of 18 years GVF to V4e was similar for both cohorts, followed by a more rapid decline of GVF to V4e after age of 20 years in patients with *BBS10* with RCD. The

BBS10 COD Phenotype

BBS10 RCD Phenotype




FIGURE 1. Phenotypes of patients with *BBS10* with COD compared to *BBS10* with RCD. (A) Optical coherence tomography (OCT) of case 39 at the corresponding ages of 34 and 39 years showing thinning of the retina and atrophy in the central macula with relatively preserved photoreceptors outside of this area. (B) Goldmann visual fields results (top) in patients P40 at different ages to I4e and V4e isopters showing preserved fields to the V4e isopter and significant field loss to I4e. (Center) OCT images through the fovea at different ages. (Lower panels) Normal dark-adapted two-color static perimetry profiles across the horizontal meridian; light-adapted profiles show measurable but reduced cone function across 60 degrees of the profile. (C) Same order of phenotyping for P41. (D) ERG of the 3 COD cases; three first ERG tracings are of patients: P40 at age 16 years, P41 at age 13 years, and P39 at age 34 years. The fourth (right) is that of a subject with normal visual function (control). DA ERGs (two upper traces for each patient ERGs) are within normal limits representing normal rod photoreceptors function in the three patients. LA ERGs (two lower traces for each patient ERGs) are reduced representing severely attenuated cone function in these patients. Taken together, these ERGs are consistent with cone dystrophy. DA, dark adapted; LA, light adapted; ERG, full field electroretinogram; X axis, time in msec; Y axis, amplitude μ V. (E) Modeling of two of the COD variants were

created from the mammalian chaperonin TRiC/CCT (PDB ID 3IYG) (5). Upper panel; (top left) Monomer structure showing the position of Ile407 (*green sticks*) and bound nucleotide (ADP, *orange sticks*). The small translated portion of the monomer that remains with the Glu61* alteration is shown in *light green*, (*top right*) oligomeric ring chaperonin structure with magnification at Ile407. Ile407 is shown to lie at an intersubunit interface near the bound ADP (*orange sticks*), the close-up of Ile407 residue position illustrates proximity to the central catalytic cavity and bound nucleotide. *Middle panel*; ClustalW alignment of selected chaperonin sequences showing conservation of the Ile407 and following acidic residue (Glu in BBS10). *Lower panel*; Comparison of open and closed forms of chaperonins. Movement of the Ile407 helix is illustrated between the open (*purple*) and closed (*magenta*) forms of GroEL/GroES. The catalytic acid of chaperonins is shown as sticks, in proximity to bound ADP analog (present in solved structure). After ATP hydrolysis, the helix rotates and moves as part of the twist mechanism of facilitated substrate protein folding that the chaperonin catalyses. Ile407 is on the opposite end of the helix, and is shown as stick-like structures. (F–H) Examples of three patients with BBS10-RCD at different ages.

oldest patients with BBS1 with a recordable field was 44.9 years, whereas for patients with BBS10 it was 25 years.

Examples of the BBS10-RCD phenotype are shown in **Figures 1F–H** contrasting with that of BBS10-COD cases (see **Figs. 1B, 1C top**). Dark-adapted chromatic horizontal static perimetry profiles performed only in patients with BBS10 40 and 41 were within normal limits while light-adapted profiles showed measurable but reduced cone function across 60 degrees (see **Figs. 1B, 1C lower panels**).

The “Systemic” BBS Phenotype may be Very Subtle

All participants except the three cases of BBS10-COD (cases 39–41) had one to several extraocular features reminiscent of BBS. The molecular diagnosis of the three patients with BBS10-COD was from retinal degeneration gene panel testing as they were not suspected of having BBS. The availability of information about common systemic BBS features was variable (see **Table 2**).¹⁸

The most prevalent extraocular features were digital anomalies (postaxial polydactyly, syndactyly, or brachydactyly), present in 96% of patients with BBS1 and 82% of patients with BBS10; followed by developmental delay, poor coordination, and kidney and liver anomalies. Because data were not available for every feature in each patient, an estimation of the frequency of each sign was impossible. Some details on part of this cohort were previously published.^{2–4,22,50,51}

Refractive Errors Were Present in 90%

Half of the 21 documented patients with BBS1 were myopic whereas the other half were hyperopic. Twelve (57%) individuals had significant astigmatism (>2 D) in combination with either myopia or hyperopia. For patients with BBS10, myopia was present in 16 (69%) of the 27 documented cases, whereas emmetropia was only seen in 3 (13%) and astigmatism was observed in about half (46%). The myopic skew in patients with BBS10-RCD compared to patients with BBS1 was statistically significant ($P = 0.046$). The three patients with BBS10-COD were also myopic (spherical equivalent: –8.0 D, –1.5 D, and –4.5 D, respectively).

Nyctalopia was Common by the First Decade and Cataracts by the Second Decade

Nyctalopia was an early symptom except in the three BBS10-COD cases. Only the eldest patient with BBS10-COD experienced photophobia at the age of 36 years.

Cataracts were documented at the mean age of 18.4 years in patients with BBS10-RCD ($n = 18$) compared to 27.4 years in patients with BBS1 ($n = 24$; see **Table 1**).

Features of Retinal Degeneration are not Specific to BBS

Retinal features in both BBS1 and BBS10-RCD cohorts showed advanced retinal degeneration with optic disc pallor, blood vessel attenuation, retinal thinning, and maculopathy, as published previously and are not specific to BBS.^{2,26}

OCT showed loss of structural integrity and markedly thinned outer retina (see **Figs. 1F–H**) and FAF had a characteristic granular pattern as previously-reported.^{2,9,52} Whereas the BBS10-COD phenotype presenting with a maculopathy, as in case 39, had well-maintained retinal lamination compared to patients with BBS10-RCD of similar ages (see **Fig. 1**).

Genetic Analyses

Participants had confirmed biallelic variants in BBS1 or BBS10 genes, which included 11 novel variants (32%). In the 38 patients with BBS1, there was a previously documented enrichment for a common missense variant c.1169T>G, p.Met390Arg present in 31 (81.5%) patients, of whom 24 (63%) were homozygotes (see **Table 2**).^{9,52} It is known that 80% of Caucasian patients carry this missense variant.⁵³ There are suggestions that this variation is a result of “hot-spot” in the gene and is the effect of multiple mutations having occurred independently at the same nucleotide. Therefore, there is a possibility that c.1169T>G, p.Met390Arg happened once, a long time ago, and was spread by emigration from its source community.^{54,55}

The BBS10 cohort was characterized by a total of 22 presumed pathogenic variants, showing more allelic heterogeneity than seen in the patients with BBS1. The c.271dup, p.(Cys91Leufs*5) and c.145C>T, p.(Arg49Trp) variants were by far the most common variants.

Two brothers with BBS10-COD (cases 40 and 41) were compound heterozygotes for novel variants: c.226C>T, p.(Leu76Phe) and c.181G>T, p.(Glu61*); whereas the third patient was homozygous for missense variant c.1120T>C, p.(Ile407Thr), which is rare and was seen once as heterozygous in a patient with BBS, but never observed as homozygous. Previously, the variant c.226C>T, p.(Leu76Phe) was reported as a compound heterozygote and predicted damaging, while c.181G>T, p.(Glu61*) is novel, not reported in ClinVar and gnomAD. As the phenotype was different, protein modeling was performed to further validate pathogenicity of c.1220T>C, p.(Ile407Thr) and c.181G>T, p.(Glu61*) using the mammalian chaperonin TRiC/CCT (PDB 3IYG; see **Fig. 1E**).⁴⁶ The models produced (Phyre2) had a confidence score of 100, with 22% sequence identity, and 41% sequence homology. This type of chaperonin, an ATPase, forms oligomeric homomultimers (double ring hexadecamers) as functional units. Because the highly




FIGURE 2. Difference in the visual acuity and visual field changes in between patients with *BBS1* and patients with *BBS10* over time. (A) Comparison among patients with *BBS1*, patients with *BBS10*-RCD, and patients with *BBS10*-COD. Blue trend line corresponds to patients with *BBS10* with RCD, red trend line to patients with *BBS1*, and green trend line to patients with *BBS10* with COD. Each dot represents VA results for each patient in the three BBS cohorts. Visual acuity had a linear decline over time in each cohort with patients with *BBS10*-RCD showing the fastest change, followed by patients with *BBS1*. The slowest progression was observed in patients with *BBS10* with COD. VA, visual acuity; LogMAR, the Logarithm of the Minimum Angle of Resolution; RCD, rod-cone dystrophy; COD, cone dystrophy. (B) Change in GVF diameter to III4e isopter in all patients with *BBS1* and patients with *BBS10*-RCD dystrophy. Patients with *BBS10*-RCD had more constricted visual fields to III4e stimuli earlier compared to patients with *BBS1* of the same age. GVF, Goldmann visual field; RCD, rod-cone dystrophy. Red trend line corresponds to patients with *BBS1* and blue trend line to patients with *BBS10*-RCD. Each dot represents the mean diameter (right and left eyes) of available GVF to III4e isopter.

conserved p.(Ile407) is present at an intersubunit interface, a mutation to threonine could alter how ATP hydrolysis induces the protein conformation changes, which is vital to chaperone function.⁴⁷ The Glu61* is predicted to cause a null protein monomer, making it impossible for the large multi-meric structure to form. A completely nonfunctional protein would result. It is possible that the milder phenotype associated with the Ile407 and Leu76Phe variants related to a milder effect on *BBS10* function that among the other mutations noted which were mostly null.

DISCUSSION

Although patients with BBS are known to have variable phenotypic severity, retinal degeneration is the feature always present, is relentlessly progressive and leads to legal blindness in late teenage years or young adulthood. Little was known about the natural history in molecularly characterized patients. This large genotyped cohort of patients allowed comparison of the natural history of vision loss related to the most commonly involved genes, *BBS1* and *BBS10*, together accounting for over 40% of BBS cases.^{4,6,56}

Murine studies have been useful in further understanding BBS phenotypes as the genetic subtypes largely recapitulate the human phenotype.^{57–59} Recent work by Kretschmer et al.⁶⁰ showed retinal degeneration phenotype differences among *Bbs5*, *6*, and *8* mice, with *Bbs8* deficient mice showing the fastest rate of retinal degeneration. In contrast, the loss of *Bbs5* (another BBSome component) showed very little degeneration. The retinal degeneration in the *Bbs10*^{-/-} mouse model has recently been documented to progress more rapidly and to be more severe than *Bbs1*^{M390R} based on functional vision measured by a visually guided swim assay, paralleling what our current study found in humans (A.V. Drack MD, personal communication, October 2020; Drack AV, et al. IOVS 2021; 62: ARVO E-Abstract 1178).

What did we Learn About Visual Function in Patients With BBS-related Disease?

In the last 25 years, we learned that BBS is a genetically heterogeneous group of disorders with phenotypic and molecular overlap with other ciliopathies. Efforts to characterize the ocular phenotype of clinically defined cohorts of patients with BBS revealed important basic characteristics of BBS, although these may not reflect BBS gene-related disease subtype.^{30,32,33,52,61–65} For example, nyctalopia is an early symptom, photophobia is variable and manifests at different ages, and the majority of patients were reported to be myopic and develop cataract in early teenage years. The early phase of the disease can be missed as it is often *sine pigmento*, and the fundus changes do not have BBS-specific characteristics.^{32,64} Riise^{30,31} and Fulton et al.³⁴ evaluated visual function changes in young cohorts and reported variability in VA decline and severe loss of VF ($n = 18$),⁶⁴ which supports our observations, except that we see differences between patients with *BBS1* and patients with *BBS10*. ERG recordings indicated early involvement of rod photoreceptors which is similar to our findings.^{32,63,64}

In our cohort, when the ERG was recordable, we report a predominant RCD phenotype (78% *BBS1* and 85% *BBS10*), a COD phenotype in patients with *BBS1* and a COD phenotype only in patients with *BBS10*. Cone dystrophy was previously reported in a patient with a systemic BBS phenotype and variants in *BBS6*, unlike our COD cases.²⁹ Other

cases of non-syndromic *BBS*-related RCD disease were previously reported,^{27,66} but we report for the first time a pure cone dystrophy phenotype in only one case with hand polydactyly.

In our study, refractive errors are common in BBS and correction often benefits the patients despite the retinal degeneration; myopia was most prevalent in patients with *BBS10*. Comparing patients with *BBS1* to patients with *BBS10*, there was a significant difference in changes in visual acuity and visual field, changes being more severe and earlier in patients with *BBS10*.

Our work supports previous studies that suggested that pathogenic variants in chaperonin-like genes (*MKKS/BBS6*, *BBS10*, and *BBS12*) usually lead to a more severe phenotype than those with changes affecting BBSome components, such as *BBS1*.^{4,20,67}

Strengths of our study include the large, balanced, cohort size of genotyped patients, the report of a novel COD phenotype in 3 patients with *BBS10*-related retinal degeneration, the longitudinal data available and that the data was captured at a wide range of ages. However, availability of the data varied at each site in part owing to the fact that no formal guidelines exist for the evaluation of these patients unlike what was recently developed for Joubert syndrome.⁶⁸ In addition, the cognition and/or behavioral characteristic of some patients would not always allow comprehensive testing. These factors together with the allelic heterogeneity precludes any mutation-phenotypic interpretation.

We believe that a prospective study would better capture uniform health parameters, but these carry time- and cost-related limitations as most inherited retinal diseases progress over years. Our multicenter retrospective approach provided valuable information in a reasonable time frame. With the developments in gene therapy in *Bbs* mouse-models: improving the electrophysiological responses in *Bbs4*^{-/-} mice, and the recent success in rescuing function in the *Bbs10* model by sustainable effect on the improvement of rod- and cone responses over 1 year,^{69–71} 2002 (Drack AV, et al. IOVS 2021; 62: ARVO E-Abstract 1178) the recent identification of a naturally occurring non-human primate model of BBS (type 7)⁷² and the success of *RPE65* gene replacement therapy,⁷³ there is enthusiasm and hope to make *BBS*-related retinal degeneration a treatable condition.

Our retrospective study on the natural history of visual function in the largest cohort of patients with *BBS1* and patients with *BBS10*, showed that the retinal degeneration time course of *BBS10*-RCD is more rapidly progressive than that of *BBS1*-related disease, which should be considered in the planning of treatment trials for these patients.

In summary, we have highlighted differences between the *BBS1* and *BBS10* phenotypes. The loss in visual function for patients with *BBS10* is earlier and somewhat more severe than for patients with *BBS1*. The gene specific phenotypic differences are supported by data of recent murine studies also showing phenotypic differences among genetic subtypes.⁶⁰ The natural history of the *BBS1* and *BBS10*-related retinal degeneration remains somewhat incomplete as in many cases the age at which the ERG became nondetectable could not be captured and was possibly earlier than documented.

Acknowledgments

The authors thank all the patients and families who participated in this study.

Supported by Fighting Blindness Canada, Henry Brent Chair in Innovative Pediatric Ophthalmology Research (EH), Career Development Award (Foundation Fighting Blindness, USA) (A.V.), Brendan Eye Research Fund (E.H. and A.V.), Foundation Fighting Blindness and Research to Prevent Blindness (UCSF) (J.L.D.). Hope for Vision, Macula Vision Research Foundation, The Pennsylvania Lions Sight Conservation, Research Foundation (T. S. A.).

Disclosure: **M.K. Grudzinska Pechhacker**, None; **S.G. Jacobson**, None; **A.V. Drack**, None; **M.D. Scipio**, None; **I. Strubbe**, None; **W. Pfeifer**, None; **J.L. Duncan**, Foundation Fighting Blindness and Research to Prevent Blindness (UCSF). Acucela (F), AGTC (C), AbbVie (F), Astellas Institute for Regenerative Medicine (C), Editas (C), Eloxx (C), Biogen/Nightstarx (F, C), Gyroscope (C), ProQR (C), Spark (C), SparingVision (S), Vedere Bio (S), Horama (C), Miller Medical Communications (C). **H. Dollfus**, None; **N. Goetz**, None; **J. Muller**, None; **A.L. Vincent**, None; **T.S. Aleman**, Hope for Vision, Macula Vision Research Foundation, The Pennsylvania Lions Sight Conservation, Research Foundation. **A. Tumber**, None; **C. Van Cauwenbergh**, None; **E. De Baere**, None; **E. Bedoukian**, None; **B.P. Leroy**, Bayer (C), GenSight Therapeutics (C, F), IVERIC Bio (C, F), LookoutGTX (C), Novartis Pharma International & Belgium (C, F), Spark Therapeutics Inc. (C, F), ProQR Therapeutics (C, F), REGENXBIO (C), Vedere Bio (C). **J.T. Maynes**, Wasser Chair in Anesthesia and Pain Medicine **F.L. Munier**, None; **E. Tavares**, None; **E. Saleh**, None; **A. Vincent**, Career Development Award (Foundation Fighting Blindness, USA), Brendan Eye Research Fund. **E. Héon**, Fighting Blindness Canada, Henry Brent Chair in Innovative Pediatric Ophthalmology Research, Brendan Eye Research Fund. Novartis (C, R), Janssen (C), Deep Genomics (S)

References

- Heon E, Westall C, Carmi R, et al. Ocular phenotypes of three genetic variants of Bardet-Biedl syndrome. *Am J Med Genet A*. 2005;132A:283–287.
- Gerth C, Zawadzki RJ, Werner JS, Heon E. Retinal morphology in patients with BBS1 and BBS10 related Bardet-Biedl Syndrome evaluated by Fourier-domain optical coherence tomography. *Vision Res*. 2008;48:392–399.
- Kerr EN, Bhan A, Heon E. Exploration of the cognitive, adaptive and behavioral functioning of patients affected with Bardet-Biedl syndrome. *Clin Genet*. 2016;89:426–433.
- Billingsley G, Bin J, Fieggen KJ, et al. Mutations in chaperonin-like BBS genes are a major contributor to disease development in a multiethnic Bardet-Biedl syndrome patient population. *J Med Genet*. 2010;47:453–463.
- Mockel A, Perdomo Y, Stutzmann F, Letsch J, Marion V, Dollfus H. Retinal dystrophy in Bardet-Biedl syndrome and related syndromic ciliopathies. *Prog Retin Eye Res*. 2011;30:258–274.
- Forsythe E, Beales PL. Bardet-Biedl syndrome. *Eur J Hum Genet*. 2013;21:8–13.
- Khan SA, Muhammad N, Khan MA, Kamal A, Rehman ZU, Khan S. Genetics of human Bardet-Biedl syndrome, an updates. *Clin Genet*. 2016;90:3–15.
- Gouronc A, Zilliox V, Jacquemont M-L, et al. High prevalence of Bardet-Biedl syndrome in La Réunion Island is due to a founder variant in ARL6/BBS3. *Clinical genetics*. 2020;98:166–171.
- Mykytyn K, Nishimura DY, Searby CC, et al. Identification of the gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human obesity syndrome. *Nat Genet*. 2002;31:435–438.
- Stoetzel C, Laurier V, Davis EE, et al. BBS10 encodes a vertebrate-specific chaperonin-like protein and is a major BBS locus. *Nat Genet*. 2006;38:521–524.
- Zhang Q, Yu D, Seo S, Stone EM, Sheffield VC. Intrinsic protein-protein interaction-mediated and chaperonin-assisted sequential assembly of stable Bardet-Biedl syndrome protein complex, the BBSome. *J Biol Chem*. 2012;287:20625–20635.
- Hernandez-Hernandez V, Pravincumar P, Diaz-Font A, et al. Bardet-Biedl syndrome proteins control the cilia length through regulation of actin polymerization. *Hum Mol Genet*. 2013;22:3858–3868.
- Jin H, White SR, Shida T, et al. The conserved Bardet-Biedl syndrome proteins assemble a coat that traffics membrane proteins to cilia. *Cell*. 2010;141:1208–1219.
- Loktev AV, Zhang Q, Beck JS, et al. A BBSome subunit links ciliogenesis, microtubule stability, and acetylation. *Dev Cell*. 2008;15:854–865.
- Seo S, Baye LM, Schulz NP, et al. BBS6, BBS10, and BBS12 form a complex with CCT/TRiC family chaperonins and mediate BBSome assembly. *Proc Natl Acad Sci USA*. 2010;107:1488–1493.
- Katsanis N, Beales PL, Woods MO, et al. Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet-Biedl syndrome. *Nat Genet*. 2000;26:67–70.
- Slavotinek AM, Stone EM, Mykytyn K, et al. Mutations in MKKS cause Bardet-Biedl syndrome. *Nat Genet*. 2000;26:15–16.
- Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. *J Med Genet*. 1999;36:437–446.
- Moore SJ, Green JS, Fan Y, et al. Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: a 22-year prospective, population-based, cohort study. *Am J Med Genet A*. 2005;132A:352–360.
- Muller J, Stoetzel C, Vincent MC, et al. Identification of 28 novel mutations in the Bardet-Biedl syndrome genes: the burden of private mutations in an extensively heterogeneous disease. *Hum Genet*. 2010;127:583–593.
- Chen J, Smaoui N, Hammer MB, et al. Molecular analysis of Bardet-Biedl syndrome families: report of 21 novel mutations in 10 genes. *Invest Ophthalmol Vis Sci*. 2011;52:5317–5324.
- Billingsley G, Vincent A, Deveault C, Heon E. Mutational analysis of SDCCAG8 in Bardet-Biedl syndrome patients with renal involvement and absent polydactyly. *Ophthalmic Genet*. 2012;33:150–154.
- Heon E, Kim G, Qin S, et al. Mutations in C8ORF37 cause Bardet Biedl syndrome (BBS21). *Hum Mol Genet*. 2016;25:2283–2294.
- Lindstrand A, Frangakis S, Carvalho CM, et al. Copy-Number Variation Contributes to the Mutational Load of Bardet-Biedl Syndrome. *Am J Hum Genet*. 2016;99:318–336.
- Dyer DS, Wilson ME, Small KW, Pai GS. Alstrom syndrome: a case misdiagnosed as Bardet-Biedl syndrome. *J Pediatr Ophthalmol Strabismus*. 1994;31:272–274.
- Estrada-Cuzcano A, Koenekoop RK, Senechal A, et al. BBS1 mutations in a wide spectrum of phenotypes ranging from nonsyndromic retinitis pigmentosa to Bardet-Biedl syndrome. *Arch Ophthalmol*. 2012;130:1425–1432.
- Khan AO, Decker E, Bachmann N, Bolz HJ, Bergmann C. C8orf37 is mutated in Bardet-Biedl syndrome and constitutes a locus allelic to non-syndromic retinal dystrophies. *Ophthalmic Genet*. 2016;37:290–293.
- den Hollander AI, Koenekoop RK, Yzer S, et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. *Am J Hum Genet*. 2006;79:556–561.
- Scheidecker S, Hull S, Perdomo Y, et al. Predominantly Cone-System Dysfunction as Rare Form of Retinal Degeneration in Patients With Molecularly Confirmed Bardet-Biedl Syndrome. *Am J Ophthalmol*. 2015;160:364–372.e361.

30. Riise R. Visual function in Laurence-Moon-Bardet-Biedl syndrome. A survey of 26 cases. *Acta Ophthalmol Suppl.* 1987;182:128–131.
31. Riise R. Laurence-Moon-Bardet-Biedl syndrome. Clinical, electrophysiological and genetic aspects. *Acta Ophthalmol Scand Suppl.* 1998;226:1–28.
32. Jacobson SG, Borruat FX, Apathy PP. Patterns of rod and cone dysfunction in Bardet-Biedl syndrome. *Am J Ophthalmol.* 1990;109:676–688.
33. Iannaccone A, De Propriis G, Roncati S, Rispoli E, Del Porto G, Pannarale MR. The ocular phenotype of the Bardet-Biedl syndrome. Comparison to non-syndromic retinitis pigmentosa. *Ophthalmic Genet.* 1997;18:13–26.
34. Fulton AB, Hansen RM, Glynn RJ. Natural course of visual functions in the Bardet-Biedl syndrome. *Arch Ophthalmol.* 1993;111:1500–1506.
35. Datta P, Allamargot C, Hudson JS, et al. Accumulation of non-outer segment proteins in the outer segment underlies photoreceptor degeneration in Bardet-Biedl syndrome. *Proc Natl Acad Sci USA.* 2015;112:E4400–E4409.
36. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. *Lancet.* 2017;390:849–860.
37. Maguire AM, Russell S, Wellman JA, et al. Efficacy, Safety, and Durability of Voretigene Neparovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. *Ophthalmology.* 2019;126:1273–1285.
38. Bach M, Brigell MG, Hawlina M, et al. ISCEV standard for clinical pattern electroretinography (PERG): 2012 update. *Doc Ophthalmol.* 2013;126:1–7.
39. McCulloch DL, Marmor MF, Brigell MG, et al. ISCEV Standard for full-field clinical electroretinography (2015 update). *Doc Ophthalmol.* 2015;130:1–12.
40. McAnany JJ, Genead MA, Walia S, et al. Visual acuity changes in patients with leber congenital amaurosis and mutations in CEP290. *JAMA Ophthalmol.* 2013;131:178–182.
41. Grover S, Fishman GA, Anderson RJ, et al. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. *Ophthalmology.* 1999;106:1780–1785.
42. RStudio Team (2020) *RT. RStudio: Integrated Development for R.* (Computer Software Version 0.98.1074.) Boston, MA: RStudio, PBC; 2020.
43. Wickham H, Sievert C. *ggplot2: elegant graphics for data analysis.* New York, NY: Springer International Publishing; 2016.
44. den Dunnen JT, Dalgleish R, Maglott DR, et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. *Hum Mutat.* 2016;37:564–569.
45. Chaudhry C, Horwich AL, Brunger AT, Adams PD. Exploring the structural dynamics of the E.coli chaperonin GroEL using translation-libration-screw crystallographic refinement of intermediate states. *J Mol Biol.* 2004;342:229–245.
46. Cong Y, Baker ML, Jakana J, et al. 4.0-Å resolution cryo-EM structure of the mammalian chaperonin TRiC/CCT reveals its unique subunit arrangement. *Proc Natl Acad Sci USA.* 2010;107:4967–4972.
47. de Groot BL, Vriend G, Berendsen HJ. Conformational changes in the chaperonin GroEL: new insights into the allosteric mechanism. *J Mol Biol.* 1999;286:1241–1249.
48. Pereira JH, Ralston CY, Douglas NR, et al. Crystal structures of a group II chaperonin reveal the open and closed states associated with the protein folding cycle. *J Biol Chem.* 2010;285:27958–27966.
49. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal for protein modeling, prediction and analysis. *Nature Protocols.* 2015;10:845–858.
50. Deveault C, Billingsley G, Duncan JL, et al. BBS genotype-phenotype assessment of a multiethnic patient cohort calls for a revision of the disease definition. *Hum Mutat.* 2011;32:610–619.
51. Tavares E, Tang CY, Vig A, et al. Retrotransposon insertion as a novel mutational event in Bardet-Biedl syndrome. *Mol Genet Genomic Med.* 2019;7:e00521.
52. Azari AA, Aleman TS, Cideciyan AV, et al. Retinal disease expression in Bardet-Biedl syndrome-1 (BBS1) is a spectrum from maculopathy to retina-wide degeneration. *Invest Ophthalmol Vis Sci.* 2006;47:5004–5010.
53. Mykytyn K, Nishimura DY, Searby CC, et al. Evaluation of complex inheritance involving the most common Bardet-Biedl syndrome locus (BBS1). *Am J Hum Genet.* 2003;72:429–437.
54. Young TL, Woods MO, Parfrey PS, Green JS, Hefferton D, Davidson WS. A founder effect in the newfoundland population reduces the Bardet-Biedl syndrome I (BBS1) interval to 1 cM. *Am J Hum Genet.* 1999;65:1680–1687.
55. Hjortshøj TD, Grønsvov K, Brøndum-Nielsen K, Rosenberg T. A novel founder BBS1 mutation explains a unique high prevalence of Bardet-Biedl syndrome in the Faroe Islands. *Br J Ophthalmol.* 2009;93:409–413.
56. Tsang SH, Aycinena ARP, Sharma T. Ciliopathy: Bardet-Biedl Syndrome. *Adv Exp Med Biol.* 2018;1085:171–174.
57. Fath MA, Mullins RF, Searby C, et al. Mkks-null mice have a phenotype resembling Bardet-Biedl syndrome. *Hum Mol Genet.* 2005;14:1109–1118.
58. Mykytyn K, Mullins RF, Andrews M, et al. Bardet-Biedl syndrome type 4 (BBS4)-null mice implicate Bbs4 in flagella formation but not global cilia assembly. *Proc Natl Acad Sci USA.* 2004;101:8664–8669.
59. Zhang Q, Nishimura D, Seo S, et al. Bardet-Biedl syndrome 3 (Bbs3) knockout mouse model reveals common BBS-associated phenotypes and Bbs3 unique phenotypes. *Proc Natl Acad Sci USA.* 2011;108:20678–20683.
60. Kretschmer V, Patnaik SR, Kretschmer F, Chawda MM, Hernandez-Hernandez V, May-Simera HL. Progressive Characterization of Visual Phenotype in Bardet-Biedl Syndrome Mutant Mice. *Invest Ophthalmol Vis Sci.* 2019;60:1132–1143.
61. Stanescu B, Wawernia E. Electroretinographic and EEG findings in the Laurence-Moon-Bardet-Biedl syndrome. *Electroencephalogr Clin Neurophysiol.* 1971;30:364–365.
62. Prospero L, Cordella M, Bernasconi S. Electroretinography and diagnosis of the Laurence-Moon-Bardet-Biedl syndrome in childhood. *J Pediatr Ophthalmol.* 1977;14:305–308.
63. Riise R, Andreasson S, Tornqvist K. Full-field electroretinograms in individuals with the Laurence-Mood-Bardet-Biedl syndrome. *Acta Ophthalmol Scand.* 1996;74:618–620.
64. Riise R, Andreasson S, Wright AF, Tornqvist K. Ocular findings in the Laurence-Moon-Bardet-Biedl syndrome. *Acta Ophthalmol Scand.* 1996;74:612–617.
65. Cannon PS, Clayton-Smith J, Beales PL, Lloyd IC. Bardet-Biedl syndrome: an atypical phenotype in brothers with a proven BBS1 mutation. *Ophthalmic Genet.* 2008;29:128–132.
66. Estrada-Cuzcano A, Roepman R, Cremers FP, den Hollander AI, Mans DA. Non-syndromic retinal ciliopathies: translating gene discovery into therapy. *Hum Mol Genet.* 2012;21:R111–R124.
67. Alvarez-Satta M, Castro-Sanchez S, Pereiro I, et al. Overview of Bardet-Biedl syndrome in Spain: identification of novel mutations in BBS1, BBS10 and BBS12 genes. *Clin Genet.* 2014;86:601–602.
68. Bachmann-Gagescu R, Dempsey JC, Bulgheroni S, et al. Healthcare recommendations for Joubert syndrome. *Am J Med Genet A.* 2020;182:229–249.

69. Chamling X, Seo S, Bugge K, et al. Ectopic expression of human BBS4 can rescue Bardet-Biedl syndrome phenotypes in Bbs4 null mice. *PLoS One*. 2013;8:e59101.
70. Simons DL, Boye SL, Hauswirth WW, Wu SM. Gene therapy prevents photoreceptor death and preserves retinal function in a Bardet-Biedl syndrome mouse model. *Proc Natl Acad Sci USA*. 2011;108:6276–6281.
71. Drack AV, Bhattarai S, Thomas J, et al. Retinal degeneration in BBS10 mice is ameliorated by subretinal gene replacement. *Invest Ophthalmol Vis Sci*. 2020;61:1914.
72. Aleman TS, O'Neil EC, O'Connor K, et al. Bardet-Biedl syndrome-7 (BBS7) shows treatment potential and a cone-rod dystrophy phenotype that recapitulates the non-human primate model. *Ophthalmic Genet*. 2021;42:252–265.
73. Maguire AM, Russell S, Chung DC, et al. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years. *Ophthalmology*. 2021;128:1460–1468.